ADVERTISEMENT

Hailong Cheng, PhD

Efficacy and Safety of SEP-363856, a Novel Psychotropic Agent with a Non-D2 Mechanism of Action, in the Treatment of Schizophrenia: A 4-Week, Randomized, Placebo-Controlled Trial

Background: SEP-363856 is a novel trace amine associated receptor-1 (TAAR1)/5-HT1A agonist with no dopamine-D2/5-HT2A antagonist activity which has shown efficacy in animal models of psyc...

Antony Loebel , MD;

Justine Kent , MD;

Robert Goldman , PhD;

Hailong Cheng , PhD;

Seth Hopkins , PhD;

Kenneth Koblan , PhD;

11/22/2019

Safety and Effectiveness of SEP-363856 in Schizophrenia: Results of a 6-month, Open-label Extension Study

Background: SEP-363856 is a novel non-D2 receptor antagonist, and preclinical data suggest that agonism at trace amine associated receptor 1 (TAAR1) and the serotonin 5-H1A receptor contr...

Robert Goldman , PhD;

Hailong Cheng , PhD;

Seth Hopkins , PhD;

Kenneth Koblan , PhD;

Justine Kent , MD;

Antony Loebel , MD;

10/08/2020

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Advertisement

Advertisement

Advertisement

Upcoming Events

November 6 ⁠–⁠ November 8

NEI Congress

November 7 ⁠–⁠ November 10

WoundCon

November 8

November 8 ⁠–⁠ November 10

Dermatology Week

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

See Full Calendar

Advertisement

Advertisement